AKRO
Price
$28.89
Change
+$0.33 (+1.16%)
Updated
Dec 26 closing price
76 days until earnings call
IDYA
Price
$25.86
Change
+$0.56 (+2.21%)
Updated
Dec 26 closing price
95 days until earnings call
Ad is loading...

AKRO vs IDYA

Header iconAKRO vs IDYA Comparison
Open Charts AKRO vs IDYABanner chart's image
Akero Therapeutics
Price$28.89
Change+$0.33 (+1.16%)
Volume$336.61K
CapitalizationN/A
IDEAYA Biosciences
Price$25.86
Change+$0.56 (+2.21%)
Volume$387.92K
CapitalizationN/A
AKRO vs IDYA Comparison Chart
Loading...
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKRO vs. IDYA commentary
Dec 27, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKRO is a Hold and IDYA is a Hold.

Ad is loading...
COMPARISON
Comparison
Dec 27, 2024
Stock price -- (AKRO: $28.89 vs. IDYA: $25.86)
Brand notoriety: AKRO and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKRO: 51% vs. IDYA: 40%
Market capitalization -- AKRO: $2.02B vs. IDYA: $2.24B
AKRO [@Biotechnology] is valued at $2.02B. IDYA’s [@Biotechnology] market capitalization is $2.24B. The market cap for tickers in the [@Biotechnology] industry ranges from $385.39B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKRO’s FA Score shows that 0 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • AKRO’s FA Score: 0 green, 5 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, AKRO is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKRO’s TA Score shows that 3 TA indicator(s) are bullish while IDYA’s TA Score has 5 bullish TA indicator(s).

  • AKRO’s TA Score: 3 bullish, 4 bearish.
  • IDYA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, IDYA is a better buy in the short-term than AKRO.

Price Growth

AKRO (@Biotechnology) experienced а +1.73% price change this week, while IDYA (@Biotechnology) price change was +4.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.89%. For the same industry, the average monthly price growth was -1.96%, and the average quarterly price growth was +5.49%.

Reported Earning Dates

AKRO is expected to report earnings on Mar 13, 2025.

IDYA is expected to report earnings on Apr 01, 2025.

Industries' Descriptions

@Biotechnology (+4.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($2.24B) has a higher market cap than AKRO($2.02B). AKRO YTD gains are higher at: 23.726 vs. IDYA (-27.319). IDYA has higher annual earnings (EBITDA): -220.54M vs. AKRO (-232.85M). IDYA has more cash in the bank: 920M vs. AKRO (717M). IDYA has less debt than AKRO: IDYA (18.8M) vs AKRO (36.4M). IDYA has higher revenues than AKRO: IDYA (3.92M) vs AKRO (0).
AKROIDYAAKRO / IDYA
Capitalization2.02B2.24B90%
EBITDA-232.85M-220.54M106%
Gain YTD23.726-27.319-87%
P/E RatioN/AN/A-
Revenue03.92M-
Total Cash717M920M78%
Total Debt36.4M18.8M194%
TECHNICAL ANALYSIS
Technical Analysis
AKROIDYA
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
72%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 11 days ago
77%
Declines
ODDS (%)
Bearish Trend 9 days ago
83%
Bearish Trend 4 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
87%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
78%
View a ticker or compare two or three
Ad is loading...
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PEQSX34.980.07
+0.20%
Putnam Large Cap Value R6
DLCEX27.050.02
+0.07%
Dana Large Cap Equity Investor
GLDIX21.35N/A
N/A
Gabelli Gold I
LISGX70.25N/A
N/A
ClearBridge Small Cap IS
FWATX14.35-0.03
-0.21%
Fidelity Advisor Multi-Asset Income A

AKRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKRO has been loosely correlated with ETNB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if AKRO jumps, then ETNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKRO
1D Price
Change %
AKRO100%
+1.16%
ETNB - AKRO
62%
Loosely correlated
+0.88%
BEAM - AKRO
44%
Loosely correlated
-0.38%
DNLI - AKRO
44%
Loosely correlated
+1.91%
PLRX - AKRO
43%
Loosely correlated
+4.00%
IDYA - AKRO
42%
Loosely correlated
+2.21%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with GRI. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then GRI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+2.21%
GRI - IDYA
54%
Loosely correlated
+1.88%
PGEN - IDYA
47%
Loosely correlated
-5.92%
ETNB - IDYA
47%
Loosely correlated
+0.88%
PLRX - IDYA
47%
Loosely correlated
+4.00%
RCKT - IDYA
47%
Loosely correlated
+2.91%
More